Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells $286,061.80 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 3,596 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $79.55, for a total value of $286,061.80. Following the transaction, the director owned 776,477 shares of the company’s stock, valued at approximately $61,768,745.35. This trade represents a 0.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Liquidia Trading Down 0.0%

Shares of Liquidia stock opened at $86.80 on Friday. The company’s fifty day simple moving average is $73.31 and its 200-day simple moving average is $51.72. The company has a market cap of $7.72 billion, a price-to-earnings ratio of 620.04 and a beta of 0.55. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 1 year low of $16.82 and a 1 year high of $91.10.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. As a group, sell-side analysts expect that Liquidia Corporation will post 3.02 EPS for the current year.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares in the last quarter. Creative Planning increased its stake in Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after acquiring an additional 7,765 shares during the period. Finally, Legal & General Group Plc increased its stake in Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after acquiring an additional 11,111 shares during the period. Institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

LQDA has been the subject of a number of research analyst reports. HC Wainwright set a $36.00 price objective on shares of Liquidia in a research report on Friday, July 24th. Stephens set a $130.00 target price on Liquidia in a research report on Friday, July 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Oppenheimer set a $75.00 price target on Liquidia in a report on Friday, June 5th. Finally, Piper Sandler set a $129.00 price objective on Liquidia in a research report on Friday, July 24th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $86.18.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).